Cargando…

Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome

Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xu-Qiao, Xing, Zhuo, Chen, Quang-Di, Salvi, Richard J., Zhang, Xuming, Tycko, Benjamin, Mobley, William C., Yu, Y. Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281234/
https://www.ncbi.nlm.nih.gov/pubmed/34276349
http://dx.doi.org/10.3389/fnagi.2021.700280
_version_ 1783722807110139904
author Chen, Xu-Qiao
Xing, Zhuo
Chen, Quang-Di
Salvi, Richard J.
Zhang, Xuming
Tycko, Benjamin
Mobley, William C.
Yu, Y. Eugene
author_facet Chen, Xu-Qiao
Xing, Zhuo
Chen, Quang-Di
Salvi, Richard J.
Zhang, Xuming
Tycko, Benjamin
Mobley, William C.
Yu, Y. Eugene
author_sort Chen, Xu-Qiao
collection PubMed
description Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abnormalities, and hearing loss. All adults with DS demonstrate AD-like brain pathology, including amyloid plaques and neurofibrillary tangles, by age 40 and dementia typically by age 60. There is compelling evidence that increased APP gene dose is necessary for AD in DS, and the mechanism for this effect has begun to emerge, implicating the C-terminal APP fragment of 99 amino acid (β-CTF). The products of other triplicated genes on Hsa21 might act to modify the impact of APP triplication by altering the overall rate of biological aging. Another important age-related DS phenotype is hearing loss, and while its mechanism is unknown, we describe its characteristics here. Moreover, immune system abnormalities in DS, involving interferon pathway genes and aging, predispose to diverse infections and might modify the severity of COVID-19. All these considerations suggest human trisomy 21 impacts several diseases in an age-dependent manner. Thus, understanding the possible aging-related mechanisms associated with these clinical manifestations of DS will facilitate therapeutic interventions in mid-to-late adulthood, while at the same time shedding light on basic mechanisms of aging.
format Online
Article
Text
id pubmed-8281234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82812342021-07-16 Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome Chen, Xu-Qiao Xing, Zhuo Chen, Quang-Di Salvi, Richard J. Zhang, Xuming Tycko, Benjamin Mobley, William C. Yu, Y. Eugene Front Aging Neurosci Neuroscience Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abnormalities, and hearing loss. All adults with DS demonstrate AD-like brain pathology, including amyloid plaques and neurofibrillary tangles, by age 40 and dementia typically by age 60. There is compelling evidence that increased APP gene dose is necessary for AD in DS, and the mechanism for this effect has begun to emerge, implicating the C-terminal APP fragment of 99 amino acid (β-CTF). The products of other triplicated genes on Hsa21 might act to modify the impact of APP triplication by altering the overall rate of biological aging. Another important age-related DS phenotype is hearing loss, and while its mechanism is unknown, we describe its characteristics here. Moreover, immune system abnormalities in DS, involving interferon pathway genes and aging, predispose to diverse infections and might modify the severity of COVID-19. All these considerations suggest human trisomy 21 impacts several diseases in an age-dependent manner. Thus, understanding the possible aging-related mechanisms associated with these clinical manifestations of DS will facilitate therapeutic interventions in mid-to-late adulthood, while at the same time shedding light on basic mechanisms of aging. Frontiers Media S.A. 2021-07-01 /pmc/articles/PMC8281234/ /pubmed/34276349 http://dx.doi.org/10.3389/fnagi.2021.700280 Text en Copyright © 2021 Chen, Xing, Chen, Salvi, Zhang, Tycko, Mobley and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Chen, Xu-Qiao
Xing, Zhuo
Chen, Quang-Di
Salvi, Richard J.
Zhang, Xuming
Tycko, Benjamin
Mobley, William C.
Yu, Y. Eugene
Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title_full Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title_fullStr Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title_full_unstemmed Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title_short Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
title_sort mechanistic analysis of age-related clinical manifestations in down syndrome
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281234/
https://www.ncbi.nlm.nih.gov/pubmed/34276349
http://dx.doi.org/10.3389/fnagi.2021.700280
work_keys_str_mv AT chenxuqiao mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT xingzhuo mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT chenquangdi mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT salvirichardj mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT zhangxuming mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT tyckobenjamin mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT mobleywilliamc mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome
AT yuyeugene mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome